JCO Article Insights: Phase I DLL3/CD3 T-Cell Engager in DLL3-Positive SCLC or NECs

<p><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "<a href= "https://ascopubs.org/doi/10.1200/JCO-25-00363" target="_blank" rel="noopener">Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas</a>."</span></p> <p class="MsoNormal" style="margin: 12pt 0in; text-align: left;" align="center"><span style= "text-decoration: underline; font-size: 12pt; font-family: arial, helvetica, sans-serif;"> <span lang="EN" style="line-height: 115%;" xml:lang= "EN"><strong>TRANSCRIP</strong>T</span></span></p> <p class="MsoNormal" style= "text-align: center; margin: 12.0pt 0in 12.0pt 0in;" align= "center"><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;"><em style="mso-bidi-font-style: normal;"> <span ...